// App-Quantinova.ai

424 : Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study

Researchers

Presenter

  • K. Chaudhuri

Principal Investigators

  • D. Weintraub

  • A. Antonini

  • W. Robieson

  • M. Li

  • K. Chatamra

  • J. Benesh

  • M. Facheris

Medical Centers

  • N/A

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Parkinson's disease

Biomarkers

  • N/A

Drug/Treatment

  • Carbidopa and Levodopa

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02549092

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved